Explore a selection of our essential drug information below, or:
Identification
- Summary
Tetrofosmin is a diphosphine complexed with technetium 99 used for imaging to determine myocardial ischemia, infarcted myocardium, and assessment of left ventricular function.
- Generic Name
- Tetrofosmin
- DrugBank Accession Number
- DB11180
- Background
Tetrofosmin was developed to overcome the non-target uptake of radioligands by the generation of hetero-atomic compounds. It presents a molecular formula of 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane. Tetrofosmin is part of the group of diphosphines. Tetrofosmin is used in conjunction with technetium Tc-99m as a radiopharmaceutical.1
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Tetrofosmin (DB11180)
- Weight
- Average: 382.462
Monoisotopic: 382.240183764 - Chemical Formula
- C18H40O4P2
- Synonyms
- Tetrofosmin
- Tetrofosmina
- External IDs
- P-53
- P53
Pharmacology
- Indication
Tetrofosmin is indicated to be used as a complex with technetium Tc-99m for scintigraphic imaging of the myocardium following separate administrations under exercise and/or resting conditions. It helps in the delineation of regions of reversible myocardial ischemia in absence of infarcted myocardium.4
This complex is also used for scintigraphic imaging of the myocardium to identify changes in perfusion induced by pharmacologic stress in patients with known or suspected coronary artery disease.4
This complex is indicated for the assessment of left ventricular function in patients evaluated for heart disease.4
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination as diagnostic agent Breast cancer Combination Product in combination with: Sodium bicarbonate (DB01390) •••••••••••• •••••••••• ••••••• ••• •••••••• Used in combination as diagnostic agent Breast cancer Combination Product in combination with: Sodium bicarbonate (DB01390) •••••••••••• •••••••••• ••••••• ••• •••••••• Used in combination as diagnostic agent Hypoperfusion Combination Product in combination with: Sodium bicarbonate (DB01390) •••••••••••• •••••••••• ••••••• ••• •••••••• Used in combination as diagnostic agent Myocardial infarction Combination Product in combination with: Sodium bicarbonate (DB01390) •••••••••••• •••••••••• ••••••• ••• •••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Refer to Technetium Tc-99m tetrofosmin
- Mechanism of action
Tetrofosmin normal biodistribution makes it suitable to be used as a myocardial agent as it is uptaken by the myocardial tissue and it presents a very low redistribution after 3-4 hours of administration.2 After distribution, tetrofosmin is a lipophilic cationic agent which is passively diffused and accumulated in viable myocardial tissue.3
- Absorption
After intravenous administration, tetrofosmin is rapidly cleared from the blood and taken up by the heart, skeletal muscle, liver, spleen and kidneys.2
- Volume of distribution
This pharmacokinetic property has not been fully studied.
- Protein binding
Refer to Technetium Tc-99m tetrofosmin
- Metabolism
This pharmacokinetic property has not been fully studied.
- Route of elimination
Refer to Technetium Tc-99m tetrofosmin
- Half-life
Refer to Technetium Tc-99m tetrofosmin
- Clearance
Refer to Technetium Tc-99m tetrofosmin
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
The toxicity of tetrofosmin as an individual agent has not been studied.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Take with food. Some studies have found that this improves imaging.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Myoview Injection, powder, lyophilized, for solution 0.23 mg/1 Intravenous Medi-Physics Inc. dba GE Healthcare 1996-02-09 Not applicable US 
Myoview Injection, powder, lyophilized, for solution 1.38 mg/1 Intravenous Medi-Physics Inc. dba GE Healthcare 2009-02-26 Not applicable US Tetrofosmin Injection, powder, lyophilized, for solution 0.35 mg/1 Intravenous Anazao Health Corporation 2012-05-23 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Tetrofosmin ROTOP 0,23 mg Kit für ein radioaktives Arzneimittel Tetrofosmin (0.23 mg) + Sodium bicarbonate (2.5 ml) Injection, powder, for solution Intravenous Rotop Pharmaka Gmb H 2018-04-30 Not applicable Austria 
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Tetrofosmin Tetrofosmin (0.35 mg/1) Injection, powder, lyophilized, for solution Intravenous Anazao Health Corporation 2012-05-23 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as organic phosphines and derivatives. These are organic compounds containing a phosphine derivative, with the general formula B1P(R2)R3 (R1-R3=alkyl, aryl).
- Kingdom
- Organic compounds
- Super Class
- Organophosphorus compounds
- Class
- Organic phosphines and derivatives
- Sub Class
- Not Available
- Direct Parent
- Organic phosphines and derivatives
- Alternative Parents
- Dialkyl ethers / Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- Aliphatic acyclic compound / Dialkyl ether / Ether / Hydrocarbon derivative / Organic oxygen compound / Organooxygen compound / Organopnictogen compound / Phosphine
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 3J0KPB596Q
- CAS number
- 127502-06-1
- InChI Key
- QCWJONLQSHEGEJ-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H40O4P2/c1-5-19-9-13-23(14-10-20-6-2)17-18-24(15-11-21-7-3)16-12-22-8-4/h5-18H2,1-4H3
- IUPAC Name
- 6,9-bis(2-ethoxyethyl)-3,12-dioxa-6,9-diphosphatetradecane
- SMILES
- CCOCCP(CCOCC)CCP(CCOCC)CCOCC
References
- General References
- Kelly JD, Forster AM, Higley B, Archer CM, Booker FS, Canning LR, Chiu KW, Edwards B, Gill HK, McPartlin M, et al.: Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging. J Nucl Med. 1993 Feb;34(2):222-7. [Article]
- Jain D, Wackers FJ, Mattera J, McMahon M, Sinusas AJ, Zaret BL: Biokinetics of technetium-99m-tetrofosmin: myocardial perfusion imaging agent: implications for a one-day imaging protocol. J Nucl Med. 1993 Aug;34(8):1254-9. [Article]
- Jadvar H. (2014). Cancer theranostics. Academic press.
- Tetrofosmin monograph [Link]
- FDA Approved Drug Products: Myoview (Kit for the preparation of technetium Tc99m tetrofosmin injection) for intravenous injection [Link]
- External Links
- PubChem Compound
- 4274
- PubChem Substance
- 347827934
- ChemSpider
- 4124
- 1311569
- ChEBI
- 135598
- ChEMBL
- CHEMBL1615784
- ZINC
- ZINC000003780929
- Wikipedia
- Technetium_(99mTc)_tetrofosmin
- FDA label
- Download (222 KB)
- MSDS
- Download (284 KB)
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data4 Completed Diagnostic Coronary Artery Disease (CAD) 1 somestatus stop reason just information to hide 3 Completed Diagnostic Coronary Artery Disease (CAD) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for solution Intravenous Injection, powder, for solution Intravenous; Parenteral 0.23 mg Injection, powder, lyophilized, for solution Intravenous 0.23 mg/1 Injection, powder, lyophilized, for solution Intravenous 1.38 mg/1 Injection, powder, for solution Intravenous 0.23 mg Injection, powder, lyophilized, for solution Intravenous 230 mcg Injection, powder, lyophilized, for solution Intravenous 0.35 mg/1 Injection, powder, for solution Intravenous Kit; powder, for solution Intravenous - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US9549999 No 2017-01-24 2030-03-10 US
Properties
- State
- Liquid
- Experimental Properties
Property Value Source boiling point (°C) 100ºC 'MSDS' water solubility Soluble 'MSDS' - Predicted Properties
Property Value Source Water Solubility 0.000664 mg/mL ALOGPS logP 3.85 ALOGPS logP 1.14 Chemaxon logS -5.8 ALOGPS pKa (Strongest Basic) 8.3 Chemaxon Physiological Charge 2 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 36.92 Å2 Chemaxon Rotatable Bond Count 19 Chemaxon Refractivity 115.73 m3·mol-1 Chemaxon Polarizability 45.62 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-056r-9347000000-2c38e9d9ea15fdd91702 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-001i-0009000000-79973081273650b0a73b Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-001i-0009000000-67e2db15753bff783fcc Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0019-0039000000-f7cd2286cdc58acaa527 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0pj0-0019000000-67a053a2259a2210e2cf Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-00mo-0591000000-7612d0322a2d7f586a98 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-000i-0189000000-e21d5422347d47e39d88 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 178.99753 predictedDeepCCS 1.0 (2019) [M+H]+ 181.35553 predictedDeepCCS 1.0 (2019) [M+Na]+ 187.80101 predictedDeepCCS 1.0 (2019)
Drug created at December 03, 2015 16:51 / Updated at February 21, 2021 18:53